GENB (Generate Biomedicines) Net Margin %: -636.99% (As of Dec. 2025)


GENB Generate Biomedicines Inc GENB
6 GF Score
Price $16.92
! 2 Warning Signs
View Full Analysis

What is Generate Biomedicines Net Margin %?

Generate Biomedicines GENB +2.18% 6 Net Margin % is -636.99% as of Dec. 2025. GuruFocus rates GENB with a GF Score™ of 6/100. The stock has 2 warning signs investors should review. Among 944 Biotechnology companies, Generate Biomedicines ranks worse than 73.52% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Generate Biomedicines's Net Income for the six months ended in Dec. 2025 was $-203.15 Mil. Generate Biomedicines's Revenue for the six months ended in Dec. 2025 was $31.89 Mil. Therefore, Generate Biomedicines's net margin for the quarter that ended in Dec. 2025 was -636.99%.

The historical rank and industry rank for Generate Biomedicines's Net Margin % or its related term are showing as below:

GENB' s Net Margin % Range Over the Past 10 Years
Min: -849.36   Med: -743.18   Max: -636.99
Current: -636.99

GENB's Net Margin % is ranked worse than
73.52% of 944 companies
in the Biotechnology industry
Industry Median: -88.815 vs GENB: -636.99

Generate Biomedicines  (NAS:GENB) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Generate Biomedicines Net Margin % Related Terms

Generate Biomedicines Net Margin % Historical Data

* Premium members only.

The historical data trend for Generate Biomedicines's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Generate Biomedicines Net Margin % Chart

Generate Biomedicines Annual Data
Trend Dec24 Dec25
Net Margin %
-849.36 -636.99

Generate Biomedicines Semi-Annual Data
Dec24 Dec25
Net Margin % -849.36 -636.99

GENB vs PVLA, SLBT, NKTR: Net Margin % Comparison

For the Biotechnology subindustry, Generate Biomedicines's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Generate Biomedicines Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Generate Biomedicines's Net Margin % distribution charts can be found below:

* The bar in red indicates where Generate Biomedicines's Net Margin % falls into.


GENB
6GF Score
Generate Biomedicines Inc GENB
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Generate Biomedicines Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Generate Biomedicines's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-203.154/31.893
=-636.99 %

Generate Biomedicines's Net Margin for the quarter that ended in Dec. 2025 is calculated as

Net Margin=Net Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-203.154/31.893
=-636.99 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -636.99% mean?
Generate Biomedicines (GENB) has a Net Margin % of -636.99% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Generate Biomedicines and its competitors. According to the industry distribution chart, Generate Biomedicines ranks #694 out of 944 companies in the Biotechnology industry, placing it in the top 73.5%.
Is Generate Biomedicines' Net Margin % too high?
Generate Biomedicines' current Net Margin % is -636.99%. Based on the distribution chart, Generate Biomedicines ranks #694 out of 944 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Generate Biomedicines has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Generate Biomedicines' Net Margin % compare to PVLA and SLBT?
According to the Biotechnology industry distribution chart, Generate Biomedicines ranks #694 out of 944 companies for Net Margin %. This places Generate Biomedicines in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Generate Biomedicines and its competitors. Generate Biomedicines's current Net Margin % is -636.99%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Generate Biomedicines stock overvalued right now?
Generate Biomedicines (GENB) has a current Net Margin % of -636.99%. The current Net Margin % is -636.99%. Generate Biomedicines' overall GF Score™ is 6/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Generate Biomedicines (GENB), the current Net Margin % is -636.99% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Generate Biomedicines Business Description

Address 101 South Street, Suite 900, Somerville, MA, USA, 02143
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
6GF Score

Get the complete analysis for GENB

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.92
Price